Literature DB >> 17497736

A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles.

Xue-Qing Zhang1, Christopher E Dahle, George J Weiner, Aliasger K Salem.   

Abstract

CpG ODN are toll-like receptor 9 (TLR9) agonists that can enhance antigen presentation by antigen presenting cells (APCs) such as dendritic cells (DCs). The most potent antigen-specific responses are seen when CpG ODN and the antigen are co-localized in the same APC. CpG ODN-antigen fusion molecules and biodegradable microparticles entrapping CpG ODN and antigen can ensure both components are delivered to the same APC. In this study, we compared the efficacy of the CpG-ODN fusion molecules against biodegradable microparticles entrapping antigen and CpG ODN. Microparticles were prepared using a double emulsion solvent evaporation methodology. CpG ODN-OVA fusion molecules were prepared by mixing maleimide-activated protein with thiolated CpG ODN. Both CpG ODN-OVA fusion molecules and microparticles co-entrapping CpG ODN and OVA generated stronger IgG2a and interferon-gamma (IFN-gamma) responses than delivery of soluble CpG ODN and OVA. The microparticles generated stronger IgG2a and IFN-gamma immune responses than did CpG ODN-antigen fusion molecules. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17497736     DOI: 10.1002/jps.20978

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  21 in total

1.  Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.

Authors:  Sean M Geary; Qiaohong Hu; Vijaya B Joshi; Ned B Bowden; Aliasger K Salem
Journal:  J Control Release       Date:  2015-09-08       Impact factor: 9.776

2.  Nanoparticles in vaccine delivery.

Authors:  Aliasger K Salem
Journal:  AAPS J       Date:  2015-01-23       Impact factor: 4.009

3.  Materials innovation for co-delivery of diverse therapeutic cargos.

Authors:  Megan E Godsey; Smruthi Suryaprakash; Kam W Leong
Journal:  RSC Adv       Date:  2013-12-21       Impact factor: 3.361

4.  Characterizing the antitumor response in mice treated with antigen-loaded polyanhydride microparticles.

Authors:  Vijaya B Joshi; Sean M Geary; Brenda R Carrillo-Conde; Balaji Narasimhan; Aliasger K Salem
Journal:  Acta Biomater       Date:  2012-11-12       Impact factor: 8.947

Review 5.  Innovative strategies for co-delivering antigens and CpG oligonucleotides.

Authors:  Yogita Krishnamachari; Aliasger K Salem
Journal:  Adv Drug Deliv Rev       Date:  2009-01-19       Impact factor: 15.470

6.  Characterization of the transgene expression generated by branched and linear polyethylenimine-plasmid DNA nanoparticles in vitro and after intraperitoneal injection in vivo.

Authors:  Janjira Intra; Aliasger K Salem
Journal:  J Control Release       Date:  2008-04-24       Impact factor: 9.776

7.  CpG oligodeoxynucleotide triggers the liver inflammatory reaction and abrogates spontaneous tolerance.

Authors:  Lian-Li Ma; Xiudan Gao; Liping Liu; Zhidan Xiang; Timothy S Blackwell; Philip Williams; Ravi S Chari; Deng-Ping Yin
Journal:  Liver Transpl       Date:  2009-08       Impact factor: 5.799

8.  Fabrication, characterization and in vitro evaluation of poly(D,L-lactide-co-glycolide) microparticles loaded with polyamidoamine-plasmid DNA dendriplexes for applications in nonviral gene delivery.

Authors:  Janjira Intra; Aliasger K Salem
Journal:  J Pharm Sci       Date:  2010-01       Impact factor: 3.534

9.  Development and Evaluation of Biodegradable Particles Coloaded With Antigen and the Toll-Like Receptor Agonist, Pentaerythritol Lipid A, as a Cancer Vaccine.

Authors:  Kawther K Ahmed; Sean M Geary; Aliasger K Salem
Journal:  J Pharm Sci       Date:  2016-01-30       Impact factor: 3.534

10.  CpG oligonucleotides as immunotherapeutic adjuvants: innovative applications and delivery strategies.

Authors:  Aliasger K Salem; George J Weiner
Journal:  Adv Drug Deliv Rev       Date:  2009-01-07       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.